Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

RXR a potential minimal residual disease target in melanoma

Jaime De Leon
July 13, 2018 11:28 PM UTC

New research into the biology of solid tumor minimal residual disease (MRD) has revealed retinoid X receptor (RXR) as a potential target to delay development of drug resistance in melanoma.

Cancer relapse is driven by MRD, which is characterized by a small population of cancer cells with intrinsic resistance to treatment. Recent studies have suggested that the cells’ resistance is not caused by mutation, but by growth of cancer stem cell populations that are inherently drug-tolerant...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ku Leuven